[Cell therapy of chronic heart failure: State of the art].
The treatment of patients with CHF using autologous bone marrow-derived mononuclear cell fraction (or its derivatives) is a promising therapy for this serious and numerous group of patients. The article analyzed international and Russian experience of using the cell therapy in patients with CHF and possibilities for extensive use of the autologous bone marrow-derived mononuclear cell fraction in clinical practice.